Stock Ratings / Health Care / HRMY / earnings

SDGR (43) AGIO (39) PRGO (41) AUPH (75) ⌘ Pro Terminal →

Harmony Biosciences Holdings Inc. (HRMY) Next Earnings Date & Expected ±8.9% Move

$38.59 +0.23% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Harmony Biosciences Holdings Inc. (HRMY) earns a Roarable Rating of B+ (Buy) with 80/100 RQD Confidence. High-quality cash engine (77% profit margin, 63% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B+ • BUY Cap $2.25B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERBUY • B+

3-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B+ · Rk A-

Each axis scored 0–20

12M PRICE TARGET CONE+9.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for HRMY)Realized 20D OHLCV Swing Band: ±8.9%

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±8.9% Swing Band

±$3.43 Expected Swing

MODEL EARNINGS SETUP GAUGE

HRMY Quantitative Pre-Earnings Setup: 80/100

Trailing EPS: $2.72 • YoY Revenue Growth: 21.5%

Model Bullish Setup (80/100)Model Risk Weight (20/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$868.5M	$158.7M	$347.9M	77.2%
FY 2024	2024-12-31	$714.7M	$145.5M	$218.7M	78.1%
FY 2023	2023-12-31	$582.0M	$128.9M	$219.4M	77.2%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating HRMY & AI Leaders Without Chasing Tops

✓Institutional whale strikes & implied earnings move audit on HRMY
✓How disciplined traders manage risk using pre-published trigger & invalidation levels
✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

HRMY // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +23.45%📐 HORIZONTAL RANGE

2026-10-30O $38.58H $39.10L $38.39C $38.59VOL 871.3K

RES: $47.87SUP: $33.63SMA50: $39.76SMA200: $34.69

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

HRMY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 HRMY Butterfly Map → + Track HRMY →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

6.0%/yr Implied 5Y Growth

vs. +21.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on HRMY today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for HRMY. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for HRMY today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (HRMY)

Health Care Rank #18 of 1016 ⚔️ SDGR vs HRMY Full Matrix →

1. Head-to-Head Health Care Peer Comparison (HRMY vs. SDGR, AGIO, PRGO, AUPH)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Harmony Biosciences Holdings Inc. (HRMY) ranks #18 by composite RQD confidence (80/100, grade B+) and #239 by equity capitalization ($2.25B). Within this direct 5-issuer industry benchmark cohort, AUPH leads on earnings valuation at 8.0x trailing P/E, while HRMY leads on capital efficiency and profitability with 63.0% ROIC and 77.2% gross margin. HRMY currently leads its immediate peer cohort in composite quantitative strength at 80/100 (B+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
HRMY ACTIVE Harmony Biosciences Holdings Inc.	B+	80/100	14.2x	77.2%	63.0%	+0.23%	$2.25B	Benchmark Subject
SDGR Schrodinger Inc.	D-	43/100	—	55.7%	-35.0%	-2.85%	$2.24B	/sdgr-vs-hrmy →
AGIO Agios Pharmaceuticals Inc.	D-	39/100	—	88.3%	-33.8%	-2.33%	$2.22B	/agio-vs-hrmy →
PRGO Perrigo Company plc	D-	41/100	—	35.1%	-13.6%	-0.13%	$2.21B	/prgo-vs-hrmy →
AUPH Aurinia Pharmaceuticals Inc	B	75/100	8.0x	88.5%	16.5%	-0.86%	$2.29B	/auph-vs-hrmy →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001802665

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Harmony Biosciences Holdings Inc. (HRMY) reported GAAP revenue of $868.5M (+21.5% vs. FY2024 revenue of $714.7M , and +49.2% cumulative change since FY2023) , GAAP net income of $158.7M, operating cash flow of $348.2M, and free cash flow of $347.9M (+59.1% YoY). On the balance sheet, HRMY closed FY2025 with $1.27B in total assets against $143.7M in total debt (Altman Z-Score: 5.38, Piotroski F-Score: 9/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$868.5M	$158.7M	$348.2M	$347.9M	$1.27B	$143.7M
FY2024 (FY)	2024-12-31	$714.7M	$145.5M	$219.8M	$218.7M	$999.2M	$163.0M
FY2023 (FY)	2023-12-31	$582.0M	$128.9M	$219.4M	$219.4M	—	—

3. HRMY Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is HRMY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Harmony Biosciences Holdings Inc. (NASDAQ: HRMY) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 80/100 at a spot price of $38.59 (+0.23% 1D, market cap $2.25B). Pillar breakdown: Fundamental Cash Engine 20/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 19/20. Across 1016 tracked Health Care issuers, HRMY ranks #18 in composite RQD confidence.

How does HRMY compare to SDGR and AGIO in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), HRMY carries a Roarable B+ (80/100 RQD), trailing P/E of 14.2x, gross margin of 77.2%, and ROIC of 63.0%. By comparison, SDGR (Schrodinger Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $2.24B) and AGIO (Agios Pharmaceuticals Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -33.8%, cap $2.22B). Among the 5-stock peer group, AUPH leads on earnings multiple (8.0x) while HRMY leads on capital efficiency (63.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for HRMY?

Per HRMY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001802665), Harmony Biosciences Holdings Inc. generated $868.5M in revenue (+21.5% YoY), $158.7M in net income, and $347.9M in free cash flow against $1.27B in total assets and $143.7M in total debt. Key quantitative strengths: Strong cash generator (77% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is HRMY trading relative to its 50-day, 200-day, and 52-week technical levels?

HRMY last traded at $38.59 (+0.23% on volume of 778,885 shares), positioning the stock -2.94% below its 50-day simple moving average ($39.76) and +11.24% above its 200-day simple moving average ($34.69). Across its 52-week range of $25.90 to $43.49, HRMY sits at the 72.1% percentile with a 14-day RSI of 51.1 (NEUTRAL RANGE) and an implied next-earnings move of ±8.9% ($35.16 to $42.02).